Role of ATP-sensitive K+ channels in relaxation of penile resistance arteries

Urology. 2004 Apr;63(4):800-5. doi: 10.1016/j.urology.2003.10.071.

Abstract

Objectives: To investigate the functional presence of adenosine triphosphate (ATP)-sensitive potassium (K+) channels (K(ATP)) in penile resistance arteries by evaluating the relaxant effects of the selective K(ATP) channel openers, cromakalim and levcromakalim, and also the involvement of K(ATP) channels in the relaxation of two drugs currently used in the treatment of erectile dysfunction (ie, prostaglandin E1 [PGE1] and sildenafil).

Methods: Penile resistance arteries were dissected from the horse corpus cavernosum and mounted in microvascular myographs for isometric tension recording. The arteries were precontracted with phenylephrine, and the responses to several vasodilators were tested in the absence and presence of K+ channel blockers.

Results: Cromakalim and levcromakalim evoked complete concentration-dependent relaxations that were blocked by 3 microm of the selective K(ATP) channel inhibitor glibenclamide. Raising extracellular K+ (25 mM) inhibited the relaxations to PGE1 and to the selective inhibitor of the cyclic adenosine monophosphate-specific phosphodiesterase (PDE4) rolipram. At a concentration selective for calcium-activated K+(K(Ca)) channels (3 mM), tetraethylammonium inhibited rolipram responses but not those of PGE1. However, glibenclamide significantly reduced the relaxation to both PGE1 and rolipram, but not those induced by the selective inhibitor of the type 5 cyclic guanosine monophosphate-specific phosphodiesterase (PDE5).

Conclusions: The present results suggest a functional role for K(ATP) channels in the relaxation of penile resistance arteries, as well as their differential involvement in the vasodilation to drugs used in the treatment of organic erectile dysfunction. They mediated relaxation to PGE1 and cyclic adenosine monophosphate-elevating agents, but not those of cyclic guanosine monophosphate-elevating agents such as sildenafil.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / antagonists & inhibitors*
  • Adenosine Triphosphate / physiology
  • Animals
  • Arteries / drug effects
  • Arteries / physiology
  • Cromakalim / pharmacology*
  • Erectile Dysfunction / drug therapy
  • Erectile Dysfunction / physiopathology
  • Glyburide / pharmacology
  • Horses
  • Humans
  • Male
  • Muscle Relaxation / drug effects
  • Muscle Relaxation / physiology
  • Muscle, Smooth, Vascular / blood supply
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology
  • Penis / blood supply*
  • Penis / drug effects
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Potassium Channel Blockers / pharmacology*
  • Potassium Channels / drug effects*
  • Potassium Channels / physiology
  • Prostaglandins E / pharmacology
  • Prostaglandins E / therapeutic use
  • Purines
  • Sildenafil Citrate
  • Sulfones
  • Vascular Resistance / drug effects
  • Vascular Resistance / physiology
  • Vasodilation / drug effects
  • Vasodilation / physiology
  • Vasodilator Agents / pharmacology*

Substances

  • Piperazines
  • Potassium Channel Blockers
  • Potassium Channels
  • Prostaglandins E
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Cromakalim
  • Adenosine Triphosphate
  • Sildenafil Citrate
  • Glyburide